Quarterly ResultMay 12, 2026, 05:12 PM
Eupraxia Q1 Net Loss $(12.65)M; Raises $63.2M; $138.88M Cash
AI Summary
Eupraxia Pharmaceuticals reported a net loss of $(12.65) million for Q1 2026, compared to $(6.77) million in Q1 2025. The company successfully completed a public offering, raising $63.2 million in gross proceeds. As of March 31, 2026, Eupraxia held $58.50 million in cash and cash equivalents and $80.38 million in short-term investments, providing a total of $138.88 million in liquidity. This capital is expected to fund operations into H2 2028, supporting further development of EP-104GI, which showed positive tissue health data in the RESOLVE trial for Eosinophilic Esophagitis.
Key Highlights
- Q1 2026 net loss was $(12.65) million, increasing from $(6.77) million in Q1 2025.
- Completed a public offering on February 20, 2026, raising $63.2 million in gross proceeds.
- Issued 7,607,145 common shares in the public offering.
- Cash and cash equivalents totaled $58.50 million as of March 31, 2026.
- Short-term investments amounted to $80.38 million as of March 31, 2026.
- Total liquidity (cash + short-term investments) was $138.88 million at quarter-end.
- Research and development expenses rose to $11.17 million in Q1 2026 from $3.85 million in Q1 2025.
- Company is well-capitalized into H2 2028, beyond key catalysts.
- Announced positive tissue health data from the RESOLVE trial for EP-104GI in EoE.